Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
This clinical trial is for patients with Hodgkin Lymphoma that has not responded to standard treatment. The purpose of this study is to determine what effects, good or bad, Temsirolimus has on Hodgkin Lymphoma. The study will also determine whether Temsirolimus is tolerated in patients with Hodgkin Lymphoma who have been previously treated with chemotherapy.
Hodgkin's Lymphoma
DRUG: Temsirolimus
To estimate the overall response rate (complete or partial response and stable disease by the IWG criteria) to temsirolimus, To estimate the overall response rate (complete or partial response and stable disease by the IWG criteria) to temsirolimus, 26 weeks
To evaluate the toxicity of temsirolimus in this patient population., To evaluate the toxicity of temsirolimus in this patient population., 26 weeks|To estimate the time to progression after treatment with temsirolimus., To estimate the time to progression after treatment with temsirolimus., 5 years|To estimate overall survival after treatment with temsirolimus., To estimate overall survival after treatment with temsirolimus., 5 years
Temsirolimus 25 mg IV infusion will be given once weekly on days 1, 8, 15 and 22 of each cycle. Patients will be assessed for response with CT scans after the second cycle, and then after every other cycle until disease progression is confirmed.

Patients will be treated with Temsirolimus until disease progression, or up to six cycles. Continuation of therapy beyond cycles is at the discretion of the investigator.